Researchers unveiled a manufacturing approach for mass production of CAR‑iNK (chimeric antigen receptor–induced natural killer) cells, addressing a bottleneck in cell‑therapy supply chains. The study details process optimizations that aim to drive down costs and increase batch sizes for off‑the‑shelf NK cell products. Authors report improvements in yield and functional consistency that could support commercial-scale runs and enable broader clinical testing. The method targets common manufacturing pain points—expansion, transduction efficiency and cryopreservation stability—and offers a path to more standardized CAR‑NK products. Investors, contract manufacturers and therapy developers will evaluate the approach for integration into GMP pipelines and for potential licensing or partnership opportunities to accelerate late‑stage programs.